http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 18 Dec 2025 07:46:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Microbix+Reports+Results+for+Q4+and+Fiscal+2025/25756096.html <p align="justify">MISSISSAUGA, Ontario, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (<strong>TSX: MBX, OTCQX: MBXBF, Microbix®</strong>), a life sciences innovator, manufacturer, and exporter, reports results for its fiscal year and fourth quarter ended September 30, 2025 (“<strong>2025</strong>” and “<strong>Q4</strong>”) with revenues for those periods reflecting reduced antigen sales into China and cancellation of a client instrument and assay development program.</p> <p align="justify"><strong>Management Discussion</strong><br/>Microbix added to both its capabilities and capacity across 2025, improving manufacturing processes, adding new products, and expanding its base of ongoing client relationships. However, setbacks relating to two clients (our distributor into China http://www.streetinsider.com/Press+Releases/Microbix+Reports+Results+for+Q4+and+Fiscal+2025/25756096.html Thu, 18 Dec 2025 07:46:00 -0500 A.17150087 MBX MBXBF O.00673997 O.49223070 http://www.streetinsider.com/Press+Releases/Microbix+Reports+Results+for+Q4+and+Fiscal+2025/25756096.html <p align="justify">MISSISSAUGA, Ontario, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (<strong>TSX: MBX, OTCQX: MBXBF, Microbix®</strong>), a life sciences innovator, manufacturer, and exporter, reports results for its fiscal year and fourth quarter ended September 30, 2025 (“<strong>2025</strong>” and “<strong>Q4</strong>”) with revenues for those periods reflecting reduced antigen sales into China and cancellation of a client instrument and assay development program.</p> <p align="justify"><strong>Management Discussion</strong><br/>Microbix added to both its capabilities and capacity across 2025, improving manufacturing processes, adding new products, and expanding its base of ongoing client relationships. However, setbacks relating to two clients (our distributor into China http://www.streetinsider.com/Press+Releases/Microbix+Reports+Results+for+Q4+and+Fiscal+2025/25756096.html Thu, 18 Dec 2025 07:46:00 -0500 A.17150087 MBX MBXBF O.00673997 O.49223070 http://www.streetinsider.com/Press+Releases/Microbix+Reports+Results+for+Q4+and+Fiscal+2025/25756096.html <p align="justify">MISSISSAUGA, Ontario, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (<strong>TSX: MBX, OTCQX: MBXBF, Microbix®</strong>), a life sciences innovator, manufacturer, and exporter, reports results for its fiscal year and fourth quarter ended September 30, 2025 (“<strong>2025</strong>” and “<strong>Q4</strong>”) with revenues for those periods reflecting reduced antigen sales into China and cancellation of a client instrument and assay development program.</p> <p align="justify"><strong>Management Discussion</strong><br/>Microbix added to both its capabilities and capacity across 2025, improving manufacturing processes, adding new products, and expanding its base of ongoing client relationships. However, setbacks relating to two clients (our distributor into China http://www.streetinsider.com/Press+Releases/Microbix+Reports+Results+for+Q4+and+Fiscal+2025/25756096.html Thu, 18 Dec 2025 07:46:00 -0500 A.17150087 MBX MBXBF O.00673997 O.49223070 http://www.streetinsider.com/Press+Releases/Microbix+Reports+Results+for+Q4+and+Fiscal+2025/25756096.html <p align="justify">MISSISSAUGA, Ontario, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (<strong>TSX: MBX, OTCQX: MBXBF, Microbix®</strong>), a life sciences innovator, manufacturer, and exporter, reports results for its fiscal year and fourth quarter ended September 30, 2025 (“<strong>2025</strong>” and “<strong>Q4</strong>”) with revenues for those periods reflecting reduced antigen sales into China and cancellation of a client instrument and assay development program.</p> <p align="justify"><strong>Management Discussion</strong><br/>Microbix added to both its capabilities and capacity across 2025, improving manufacturing processes, adding new products, and expanding its base of ongoing client relationships. However, setbacks relating to two clients (our distributor into China http://www.streetinsider.com/Press+Releases/Microbix+Reports+Results+for+Q4+and+Fiscal+2025/25756096.html Thu, 18 Dec 2025 07:46:00 -0500 A.17150087 MBX MBXBF O.00673997 O.49223070 http://www.streetinsider.com/Press+Releases/Microbix+Reports+Results+for+Q4+and+Fiscal+2025/25756096.html <p align="justify">MISSISSAUGA, Ontario, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (<strong>TSX: MBX, OTCQX: MBXBF, Microbix®</strong>), a life sciences innovator, manufacturer, and exporter, reports results for its fiscal year and fourth quarter ended September 30, 2025 (“<strong>2025</strong>” and “<strong>Q4</strong>”) with revenues for those periods reflecting reduced antigen sales into China and cancellation of a client instrument and assay development program.</p> <p align="justify"><strong>Management Discussion</strong><br/>Microbix added to both its capabilities and capacity across 2025, improving manufacturing processes, adding new products, and expanding its base of ongoing client relationships. However, setbacks relating to two clients (our distributor into China http://www.streetinsider.com/Press+Releases/Microbix+Reports+Results+for+Q4+and+Fiscal+2025/25756096.html Thu, 18 Dec 2025 07:46:00 -0500 A.17150087 MBX MBXBF O.00673997 O.49223070 http://www.streetinsider.com/Globe+Newswire/Microbix+Reports+Results+for+Q4+and+Fiscal+2025/25756096.html <p align="justify">MISSISSAUGA, Ontario, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (<strong>TSX: MBX, OTCQX: MBXBF, Microbix®</strong>), a life sciences innovator, manufacturer, and exporter, reports results for its fiscal year and fourth quarter ended September 30, 2025 (“<strong>2025</strong>” and “<strong>Q4</strong>”) with revenues for those periods reflecting reduced antigen sales into China and cancellation of a client instrument and assay development program.</p> <p align="justify"><strong>Management Discussion</strong><br/>Microbix added to both its capabilities and capacity across 2025, improving manufacturing processes, adding new products, and expanding its base of ongoing client relationships. However, setbacks relating to two clients (our distributor into China http://www.streetinsider.com/Globe+Newswire/Microbix+Reports+Results+for+Q4+and+Fiscal+2025/25756096.html Thu, 18 Dec 2025 07:46:00 -0500 A.17150087 MBX MBXBF O.00673997 O.49223070 http://www.streetinsider.com/Globe+Newswire/Microbix+Reports+Results+for+Q4+and+Fiscal+2025/25756096.html <p align="justify">MISSISSAUGA, Ontario, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (<strong>TSX: MBX, OTCQX: MBXBF, Microbix®</strong>), a life sciences innovator, manufacturer, and exporter, reports results for its fiscal year and fourth quarter ended September 30, 2025 (“<strong>2025</strong>” and “<strong>Q4</strong>”) with revenues for those periods reflecting reduced antigen sales into China and cancellation of a client instrument and assay development program.</p> <p align="justify"><strong>Management Discussion</strong><br/>Microbix added to both its capabilities and capacity across 2025, improving manufacturing processes, adding new products, and expanding its base of ongoing client relationships. However, setbacks relating to two clients (our distributor into China http://www.streetinsider.com/Globe+Newswire/Microbix+Reports+Results+for+Q4+and+Fiscal+2025/25756096.html Thu, 18 Dec 2025 07:46:00 -0500 A.17150087 MBX MBXBF O.00673997 O.49223070 http://www.streetinsider.com/Globe+Newswire/Microbix+Reports+Results+for+Q4+and+Fiscal+2025/25756096.html <p align="justify">MISSISSAUGA, Ontario, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (<strong>TSX: MBX, OTCQX: MBXBF, Microbix®</strong>), a life sciences innovator, manufacturer, and exporter, reports results for its fiscal year and fourth quarter ended September 30, 2025 (“<strong>2025</strong>” and “<strong>Q4</strong>”) with revenues for those periods reflecting reduced antigen sales into China and cancellation of a client instrument and assay development program.</p> <p align="justify"><strong>Management Discussion</strong><br/>Microbix added to both its capabilities and capacity across 2025, improving manufacturing processes, adding new products, and expanding its base of ongoing client relationships. However, setbacks relating to two clients (our distributor into China http://www.streetinsider.com/Globe+Newswire/Microbix+Reports+Results+for+Q4+and+Fiscal+2025/25756096.html Thu, 18 Dec 2025 07:46:00 -0500 A.17150087 MBX MBXBF O.00673997 O.49223070 http://www.streetinsider.com/Globe+Newswire/Microbix+Reports+Results+for+Q4+and+Fiscal+2025/25756096.html <p align="justify">MISSISSAUGA, Ontario, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (<strong>TSX: MBX, OTCQX: MBXBF, Microbix®</strong>), a life sciences innovator, manufacturer, and exporter, reports results for its fiscal year and fourth quarter ended September 30, 2025 (“<strong>2025</strong>” and “<strong>Q4</strong>”) with revenues for those periods reflecting reduced antigen sales into China and cancellation of a client instrument and assay development program.</p> <p align="justify"><strong>Management Discussion</strong><br/>Microbix added to both its capabilities and capacity across 2025, improving manufacturing processes, adding new products, and expanding its base of ongoing client relationships. However, setbacks relating to two clients (our distributor into China http://www.streetinsider.com/Globe+Newswire/Microbix+Reports+Results+for+Q4+and+Fiscal+2025/25756096.html Thu, 18 Dec 2025 07:46:00 -0500 A.17150087 MBX MBXBF O.00673997 O.49223070 http://www.streetinsider.com/Globe+Newswire/Microbix+Reports+Results+for+Q4+and+Fiscal+2025/25756096.html <p align="justify">MISSISSAUGA, Ontario, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (<strong>TSX: MBX, OTCQX: MBXBF, Microbix®</strong>), a life sciences innovator, manufacturer, and exporter, reports results for its fiscal year and fourth quarter ended September 30, 2025 (“<strong>2025</strong>” and “<strong>Q4</strong>”) with revenues for those periods reflecting reduced antigen sales into China and cancellation of a client instrument and assay development program.</p> <p align="justify"><strong>Management Discussion</strong><br/>Microbix added to both its capabilities and capacity across 2025, improving manufacturing processes, adding new products, and expanding its base of ongoing client relationships. However, setbacks relating to two clients (our distributor into China http://www.streetinsider.com/Globe+Newswire/Microbix+Reports+Results+for+Q4+and+Fiscal+2025/25756096.html Thu, 18 Dec 2025 07:46:00 -0500 A.17150087 MBX MBXBF O.00673997 O.49223070 http://www.streetinsider.com/Press+Releases/Microbix+Schedules+Release+of+Results+for+Q4+Fiscal+2025/25730519.html <p align="justify">MISSISSAUGA, Ontario, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (<strong>TSX: MBX, OTCQX: MBXBF, Microbix®</strong>), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements, management disclosure and analysis, and results news release for its fourth quarter of fiscal 2025 ended September 30, 2025 (“<strong>Q4 2025</strong>”) prior to the start of trading on December 18, 2025. At 10:00 AM ET that day, Microbix intends to hold a webinar discussion of Q4 2025 results with its CEO, CFO, and COO.</p> <p align="justify">Investor and shareholders can participate in the webinar, hosted http://www.streetinsider.com/Press+Releases/Microbix+Schedules+Release+of+Results+for+Q4+Fiscal+2025/25730519.html Thu, 11 Dec 2025 17:00:00 -0500 A.17150087 MBX MBXBF O.00673997 O.49223070 http://www.streetinsider.com/Press+Releases/Microbix+Schedules+Release+of+Results+for+Q4+Fiscal+2025/25730519.html <p align="justify">MISSISSAUGA, Ontario, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (<strong>TSX: MBX, OTCQX: MBXBF, Microbix®</strong>), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements, management disclosure and analysis, and results news release for its fourth quarter of fiscal 2025 ended September 30, 2025 (“<strong>Q4 2025</strong>”) prior to the start of trading on December 18, 2025. At 10:00 AM ET that day, Microbix intends to hold a webinar discussion of Q4 2025 results with its CEO, CFO, and COO.</p> <p align="justify">Investor and shareholders can participate in the webinar, hosted http://www.streetinsider.com/Press+Releases/Microbix+Schedules+Release+of+Results+for+Q4+Fiscal+2025/25730519.html Thu, 11 Dec 2025 17:00:00 -0500 A.17150087 MBX MBXBF O.00673997 O.49223070 http://www.streetinsider.com/Press+Releases/Microbix+Schedules+Release+of+Results+for+Q4+Fiscal+2025/25730519.html <p align="justify">MISSISSAUGA, Ontario, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (<strong>TSX: MBX, OTCQX: MBXBF, Microbix®</strong>), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements, management disclosure and analysis, and results news release for its fourth quarter of fiscal 2025 ended September 30, 2025 (“<strong>Q4 2025</strong>”) prior to the start of trading on December 18, 2025. At 10:00 AM ET that day, Microbix intends to hold a webinar discussion of Q4 2025 results with its CEO, CFO, and COO.</p> <p align="justify">Investor and shareholders can participate in the webinar, hosted http://www.streetinsider.com/Press+Releases/Microbix+Schedules+Release+of+Results+for+Q4+Fiscal+2025/25730519.html Thu, 11 Dec 2025 17:00:00 -0500 A.17150087 MBX MBXBF O.00673997 O.49223070 http://www.streetinsider.com/Press+Releases/Microbix+Schedules+Release+of+Results+for+Q4+Fiscal+2025/25730519.html <p align="justify">MISSISSAUGA, Ontario, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (<strong>TSX: MBX, OTCQX: MBXBF, Microbix®</strong>), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements, management disclosure and analysis, and results news release for its fourth quarter of fiscal 2025 ended September 30, 2025 (“<strong>Q4 2025</strong>”) prior to the start of trading on December 18, 2025. At 10:00 AM ET that day, Microbix intends to hold a webinar discussion of Q4 2025 results with its CEO, CFO, and COO.</p> <p align="justify">Investor and shareholders can participate in the webinar, hosted http://www.streetinsider.com/Press+Releases/Microbix+Schedules+Release+of+Results+for+Q4+Fiscal+2025/25730519.html Thu, 11 Dec 2025 17:00:00 -0500 A.17150087 MBX MBXBF O.00673997 O.49223070 http://www.streetinsider.com/Press+Releases/Microbix+Schedules+Release+of+Results+for+Q4+Fiscal+2025/25730519.html <p align="justify">MISSISSAUGA, Ontario, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (<strong>TSX: MBX, OTCQX: MBXBF, Microbix®</strong>), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements, management disclosure and analysis, and results news release for its fourth quarter of fiscal 2025 ended September 30, 2025 (“<strong>Q4 2025</strong>”) prior to the start of trading on December 18, 2025. At 10:00 AM ET that day, Microbix intends to hold a webinar discussion of Q4 2025 results with its CEO, CFO, and COO.</p> <p align="justify">Investor and shareholders can participate in the webinar, hosted http://www.streetinsider.com/Press+Releases/Microbix+Schedules+Release+of+Results+for+Q4+Fiscal+2025/25730519.html Thu, 11 Dec 2025 17:00:00 -0500 A.17150087 MBX MBXBF O.00673997 O.49223070 http://www.streetinsider.com/Globe+Newswire/Microbix+Schedules+Release+of+Results+for+Q4+Fiscal+2025/25730519.html <p align="justify">MISSISSAUGA, Ontario, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (<strong>TSX: MBX, OTCQX: MBXBF, Microbix®</strong>), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements, management disclosure and analysis, and results news release for its fourth quarter of fiscal 2025 ended September 30, 2025 (“<strong>Q4 2025</strong>”) prior to the start of trading on December 18, 2025. At 10:00 AM ET that day, Microbix intends to hold a webinar discussion of Q4 2025 results with its CEO, CFO, and COO.</p> <p align="justify">Investor and shareholders can participate in the webinar, hosted http://www.streetinsider.com/Globe+Newswire/Microbix+Schedules+Release+of+Results+for+Q4+Fiscal+2025/25730519.html Thu, 11 Dec 2025 17:00:00 -0500 A.17150087 MBX MBXBF O.00673997 O.49223070 http://www.streetinsider.com/Globe+Newswire/Microbix+Schedules+Release+of+Results+for+Q4+Fiscal+2025/25730519.html <p align="justify">MISSISSAUGA, Ontario, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (<strong>TSX: MBX, OTCQX: MBXBF, Microbix®</strong>), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements, management disclosure and analysis, and results news release for its fourth quarter of fiscal 2025 ended September 30, 2025 (“<strong>Q4 2025</strong>”) prior to the start of trading on December 18, 2025. At 10:00 AM ET that day, Microbix intends to hold a webinar discussion of Q4 2025 results with its CEO, CFO, and COO.</p> <p align="justify">Investor and shareholders can participate in the webinar, hosted http://www.streetinsider.com/Globe+Newswire/Microbix+Schedules+Release+of+Results+for+Q4+Fiscal+2025/25730519.html Thu, 11 Dec 2025 17:00:00 -0500 A.17150087 MBX MBXBF O.00673997 O.49223070 http://www.streetinsider.com/Globe+Newswire/Microbix+Schedules+Release+of+Results+for+Q4+Fiscal+2025/25730519.html <p align="justify">MISSISSAUGA, Ontario, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (<strong>TSX: MBX, OTCQX: MBXBF, Microbix®</strong>), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements, management disclosure and analysis, and results news release for its fourth quarter of fiscal 2025 ended September 30, 2025 (“<strong>Q4 2025</strong>”) prior to the start of trading on December 18, 2025. At 10:00 AM ET that day, Microbix intends to hold a webinar discussion of Q4 2025 results with its CEO, CFO, and COO.</p> <p align="justify">Investor and shareholders can participate in the webinar, hosted http://www.streetinsider.com/Globe+Newswire/Microbix+Schedules+Release+of+Results+for+Q4+Fiscal+2025/25730519.html Thu, 11 Dec 2025 17:00:00 -0500 A.17150087 MBX MBXBF O.00673997 O.49223070 http://www.streetinsider.com/Globe+Newswire/Microbix+Schedules+Release+of+Results+for+Q4+Fiscal+2025/25730519.html <p align="justify">MISSISSAUGA, Ontario, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (<strong>TSX: MBX, OTCQX: MBXBF, Microbix®</strong>), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements, management disclosure and analysis, and results news release for its fourth quarter of fiscal 2025 ended September 30, 2025 (“<strong>Q4 2025</strong>”) prior to the start of trading on December 18, 2025. At 10:00 AM ET that day, Microbix intends to hold a webinar discussion of Q4 2025 results with its CEO, CFO, and COO.</p> <p align="justify">Investor and shareholders can participate in the webinar, hosted http://www.streetinsider.com/Globe+Newswire/Microbix+Schedules+Release+of+Results+for+Q4+Fiscal+2025/25730519.html Thu, 11 Dec 2025 17:00:00 -0500 A.17150087 MBX MBXBF O.00673997 O.49223070 http://www.streetinsider.com/Globe+Newswire/Microbix+Schedules+Release+of+Results+for+Q4+Fiscal+2025/25730519.html <p align="justify">MISSISSAUGA, Ontario, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (<strong>TSX: MBX, OTCQX: MBXBF, Microbix®</strong>), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements, management disclosure and analysis, and results news release for its fourth quarter of fiscal 2025 ended September 30, 2025 (“<strong>Q4 2025</strong>”) prior to the start of trading on December 18, 2025. At 10:00 AM ET that day, Microbix intends to hold a webinar discussion of Q4 2025 results with its CEO, CFO, and COO.</p> <p align="justify">Investor and shareholders can participate in the webinar, hosted http://www.streetinsider.com/Globe+Newswire/Microbix+Schedules+Release+of+Results+for+Q4+Fiscal+2025/25730519.html Thu, 11 Dec 2025 17:00:00 -0500 A.17150087 MBX MBXBF O.00673997 O.49223070 http://www.streetinsider.com/Press+Releases/Microbix+Launches+New+Products+to+Support+H3N2+Flu+Testing/25720888.html <p align="justify">MISSISSAUGA, Ontario, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (<strong>TSX: MBX, OTCQX: MBXBF, Microbix®</strong>), a life sciences innovator, manufacturer, and exporter, announces the commercial launch of <strong>QAPs™</strong> quality assessment products and availability of <strong>QUANTDx™</strong> reference materials to support antigen or molecular tests for H3N2 strains of seasonal Influenza A (a.k.a., the “<strong>Flu</strong>”).</p> <p align="justify">H3N2, alongside H1N1, is a common type of Influenza A that circulates annually, with H3N2 more prone to “antigenic drift,” changing the surface of the virus and its level of recognition by antibodies. These changes can reduce the level of protection http://www.streetinsider.com/Press+Releases/Microbix+Launches+New+Products+to+Support+H3N2+Flu+Testing/25720888.html Wed, 10 Dec 2025 07:00:00 -0500 A.17150087 A.40330213 MBX MBXBF O.00525419 O.00673997 O.49223070 http://www.streetinsider.com/Press+Releases/Microbix+Launches+New+Products+to+Support+H3N2+Flu+Testing/25720888.html <p align="justify">MISSISSAUGA, Ontario, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (<strong>TSX: MBX, OTCQX: MBXBF, Microbix®</strong>), a life sciences innovator, manufacturer, and exporter, announces the commercial launch of <strong>QAPs™</strong> quality assessment products and availability of <strong>QUANTDx™</strong> reference materials to support antigen or molecular tests for H3N2 strains of seasonal Influenza A (a.k.a., the “<strong>Flu</strong>”).</p> <p align="justify">H3N2, alongside H1N1, is a common type of Influenza A that circulates annually, with H3N2 more prone to “antigenic drift,” changing the surface of the virus and its level of recognition by antibodies. These changes can reduce the level of protection http://www.streetinsider.com/Press+Releases/Microbix+Launches+New+Products+to+Support+H3N2+Flu+Testing/25720888.html Wed, 10 Dec 2025 07:00:00 -0500 A.17150087 A.40330213 MBX MBXBF O.00525419 O.00673997 O.49223070 http://www.streetinsider.com/Press+Releases/Microbix+Launches+New+Products+to+Support+H3N2+Flu+Testing/25720888.html <p align="justify">MISSISSAUGA, Ontario, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (<strong>TSX: MBX, OTCQX: MBXBF, Microbix®</strong>), a life sciences innovator, manufacturer, and exporter, announces the commercial launch of <strong>QAPs™</strong> quality assessment products and availability of <strong>QUANTDx™</strong> reference materials to support antigen or molecular tests for H3N2 strains of seasonal Influenza A (a.k.a., the “<strong>Flu</strong>”).</p> <p align="justify">H3N2, alongside H1N1, is a common type of Influenza A that circulates annually, with H3N2 more prone to “antigenic drift,” changing the surface of the virus and its level of recognition by antibodies. These changes can reduce the level of protection http://www.streetinsider.com/Press+Releases/Microbix+Launches+New+Products+to+Support+H3N2+Flu+Testing/25720888.html Wed, 10 Dec 2025 07:00:00 -0500 A.17150087 A.40330213 MBX MBXBF O.00525419 O.00673997 O.49223070 http://www.streetinsider.com/Press+Releases/Microbix+Launches+New+Products+to+Support+H3N2+Flu+Testing/25720888.html <p align="justify">MISSISSAUGA, Ontario, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (<strong>TSX: MBX, OTCQX: MBXBF, Microbix®</strong>), a life sciences innovator, manufacturer, and exporter, announces the commercial launch of <strong>QAPs™</strong> quality assessment products and availability of <strong>QUANTDx™</strong> reference materials to support antigen or molecular tests for H3N2 strains of seasonal Influenza A (a.k.a., the “<strong>Flu</strong>”).</p> <p align="justify">H3N2, alongside H1N1, is a common type of Influenza A that circulates annually, with H3N2 more prone to “antigenic drift,” changing the surface of the virus and its level of recognition by antibodies. These changes can reduce the level of protection http://www.streetinsider.com/Press+Releases/Microbix+Launches+New+Products+to+Support+H3N2+Flu+Testing/25720888.html Wed, 10 Dec 2025 07:00:00 -0500 A.17150087 A.40330213 MBX MBXBF O.00525419 O.00673997 O.49223070 http://www.streetinsider.com/Press+Releases/Microbix+Launches+New+Products+to+Support+H3N2+Flu+Testing/25720888.html <p align="justify">MISSISSAUGA, Ontario, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (<strong>TSX: MBX, OTCQX: MBXBF, Microbix®</strong>), a life sciences innovator, manufacturer, and exporter, announces the commercial launch of <strong>QAPs™</strong> quality assessment products and availability of <strong>QUANTDx™</strong> reference materials to support antigen or molecular tests for H3N2 strains of seasonal Influenza A (a.k.a., the “<strong>Flu</strong>”).</p> <p align="justify">H3N2, alongside H1N1, is a common type of Influenza A that circulates annually, with H3N2 more prone to “antigenic drift,” changing the surface of the virus and its level of recognition by antibodies. These changes can reduce the level of protection http://www.streetinsider.com/Press+Releases/Microbix+Launches+New+Products+to+Support+H3N2+Flu+Testing/25720888.html Wed, 10 Dec 2025 07:00:00 -0500 A.17150087 A.40330213 MBX MBXBF O.00525419 O.00673997 O.49223070